

## REFERENCES

- Bartlett J , "Treatment of community-acquired pneumonia", Chemotherapy;46 Suppl 1:24-31, 2000.
- Bedos J, Azoulay-Dupuis E, Moine P, Muffat-Joly M, Veber B, Pocidalo J, and Vallee E, "Pharmacokinetic activities of ciprofloxacin and sparfloxacin in a murine pneumococcal pneumonia model: relevance for drug efficacy", The J of pharmacology and experimental therapeutics, 286: 29-35, 1998.
- Breilh D, Saux M-C, Marie P, Vergnaud J-M, Jelliffe RW, "Mixed pharmacokinetic population study and diffusion model to describe ciprofloxacin lung concentration", Computer in Biology and Medicine, 31: 147-155, 2001.
- CDC MMWR Weekly, 50 (41-48): 889-1079, 2001.
- Chamoun AJ, Conti V, Lenihan DJ, "Native valve infective endocarditis: what is the optimal timing for surgery?", Am J Med Sci;320(4):255-62, 2000 Oct.
- Cherubin CE, Eng RH , "Experience with the use of cefotaxime in the treatment of bacterial meningitis", Am J Med;80(3):398-404, 1986 Mar.
- Craig B, "Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men", Clinical Infectious Diseases, 26:1-12, 1998.
- Craig WA, "Does the dose matter ?", Clin Infect Dis, 33(suppl 3):s233-s237, 2001.
- Crokaert F, "Pharmacodynamics, a tool for a better use of antibiotics ?", Intensive Care Med, 27:340-343, 2001.
- Dean DA, Burchard KW , "Surgical perspective on invasive Candida infections", World J Surg;22(2):127-34, 1998 Feb.
- Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, and Standiford HC, "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function", Antimicrobial Agents and Chemotherapy, 31(6): 860-864, 1987.
- Engels EA, Ellis CA, Supran SE, Schmid CH, Barza M, Schenkein DP, Koc Y, Miller

Firsov AA, Vostrov SN, Shevchenko AA, and Cornaglia G, "Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against *Escherichia coli* in an in vitro dynamic model", *Antimicrobial Agents and Chemotherapy*, 41(6):1281-1287, 1997.

Firsov AA, Vostrov SN, Shevchenko AA, Zinner SH, Cornaglia G, and Portnoy YA, "MIC-based interspecies prediction of the antimicrobial effects of ciprofloxacin on bacteria of different susceptibilities in an in vitro dynamic model", *Antimicrobial Agents and Chemotherapy*, 42(11): 2848-2852, 1998.

Fisher LD, Van Belle G, "Biostatistics: A methodology for the health sciences", John Wiley & sons, Inc, 1993.

Forrest A, Ballow CH, Nix DE, Birmingham MC, "Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin", *Antimicrobial Agents and Chemotherapy*, 37(5): 1065-1072, 1993(a).

Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, and Schentag JJ, "Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients", *Antimicrobial Agents and Chemotherapy*, 37(5): 1073-1081, 1993(b).

Friedlander AM, Welkos SL, Pitt MLM, Ezzell JW, Worsham PL, Ross KJ, Ivins BE, Lowe JR, Howe GB, Mikesell P, and Lawrence WB, "Postexposure prophylaxis against experimental inhalation anthrax", *J of Infectious Diseases*, 167: 1239-1242, 1993.

Hyatt JM, McKinnon PS, Zimmer GS, and Schentag JJ, "The important of pharmacokinetic/pharmacodynamic surrogate markers to outcome: focus on antibacterial agents", *Clin Pharmacokinet*, 28(2):143-160, 1995.

Hyatt JM, Nix DE, Schentag JJ, "Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of *S pneumoniae*, *S aureus* and *P aeruginosa* for which MICs are similar", *Antimicrobial Agents and Chemotherapy*, 32(12): 2730-2737, 1994.

Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Friedlander AM, Hauer J, McDade J, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Tonat K,

"Anthrax as a biological weapon: medical and public health management", JAMA, 281(18): 1735-1745, 1999.

KB, Wong JB, "Early infection in bone marrow transplantation: quantitative study of clinical factors that affect risk", Clin Infect Dis;28(2):256-66, 1999 Feb.

Kelly DJ, Chulay JD, Mikesell P, and Friedlander AM, "Serum concentrations of penicillin, doxycycline, and ciprofloxacin during prolonged therapy in rhesus monkeys", J of Infectious Diseases, 166: 1184-1187, 1992.

Ko WC, Lee HC, Chuang YC, Liu CC, Wu JJ, "Clinical features and therapeutic implications of 104 episodes of monomicrobial *Aeromonas* bacteraemia", J Infect;40(3):267-73, 2000 May.

Kuppens SP, van de Wetering J, Boerma EC , "Acute epiglottitis as a cause of airway obstruction in an adult patient", Neth J Med;56(5):190-2, 2000 May.

Lee P, "Design and power of a population pharmacokinetic study", Pharmaceutical Research, 18 (1): 75-82, 2001.

Leggett JE, Fantin B, Ebert S, "Comparative antibiotic dose-effect relations at several dosing interval in murine pneumonitis and thigh-infection model", J Infectious Diseases, 159:281-292, 1989.

Li RC, "New pharmacodynamic parameters for antimicrobial agents", International Journal of Antimicrobial Agents, 13: 229-235, 2000.

MacGowan AP, "Role of pharmacokinetics and pharmacodynamics: does the dose matter ?", Clin Infect Dis, 33 (suppl 3): S238-S239, 2001.

MacGowan AP, Wootton M, and Holt A, "The antibacterial efficacy of levofloxacin and ciprofloxacin against *Pseudomonas aeruginosa* assessed by combining antibiotic exposure and bacterial susceptibility", J of Antimicrobial Chemotherapy, 43: 345-349, 1999.

Madaras-Kelly JK, Larson AJ, Rotschafer JC, "A pharmacodynamic evaluation of ciprofloxacin and ofloxacin against two strains of *Pseudomonas aeruginosa*", J Antimicrob Chemother, 37:703-710, 1996.

Maneechotesuwan K , "An exotic pulmonary infection in Thailand: melioidosis",  
Respirology;4(4):419-22, 1999 Dec.

McGrath BJ, Kang SL, Kaatz GW, and Rybak MJ, "Bactericidal activities of teicoplanin, vancomycin, and gentamicin alone and in combination against staphylococcus aureus in an in vitro pharmacodynamic model of endocarditis", Antimicrobial Agents and Chemotherapy, 38(8): 2034-2040, 1994.

Meselson M, Guillemin J, Hugh-Johne M, Langmuir A, Popova I, Shelokov A, Yampolskaya O, "The Sverdlovsk anthrax outbreak of 1979", Science, 226: 1202-1208, 1994.

Mouton JW, van Ogtrop ML, Andes D, and Craig WA, "Use of pharmacodynamic Indices to predict efficacy of combination therapy in vivo", Antimicrobial Agents and Chemotherapy, 43(10): 2473-2478, 1999.

Ochiai T, Ohta K, Takahashi M, Yamazaki S, Iwai T, "Fournier's gangrene: report of six cases ", Surg Today;31(6):553-6, 2001.

Patel R, Paya CV , "Infections in solid-organ transplant recipients", Clin Microbiol Rev;10(1):86-124, 1997 Jan.

Physician's Desk Reference, 55<sup>th</sup> edition, 2001.

Samuel M, Ti TY, "Interventions for treating melioidosis", Cochrane Database Syst Rev;2:CD001263, 2001.

Sanchez-Navarro A and Recio MMS, "Basis of anti-infective therapy, pharmacokinetic-pharmacodynamic criteria and methodology for dual dosage individualisation", Clin Pharmacokinet, 37(4): 289-304, 1999.

Schentag JJ, Gilliland KK, and Paladino JA, "What have we learned from pharmacokinetic and pharmacodynamic theories ?", Clin Infect Dis, 32 (suppl 1): s39-s46, 2001.

Shah A, Lettieri J, Nix D, Wilton J, and Heller AH, "Pharmacokinetics of high-dose intravenous ciprofloxacin in young and elderly and in male and female subjects", Antimicrobial Agents and Chemotherapy, 39(4): 1003-1006, 1995.

Spapen HD, Diltoer M, Huyghens LP , "Passive immunotherapy of gram-negative bacteremia, sepsis and septic shock", Acta Clin Belg;48(1):20-9, 1993.

Terzivanov D, Atanasova I, Dimitrova V, "Population pharmacokinetics of ciprofloxacin in patients with liver impairments analyzed by NPEM2 algorithm – a retrospective study", International J of Clinical Pharmacology and Therapeutics, 36(7): 376-382, 1998.

Walker D, "Human pathology inhalational disease", FDA Antiinfective Advisory Committee Meeting, July, 2000.

Wisneski RJ, "Infectious disease of the spine. Diagnostic and treatment considerations", Orthop Clin North Am;22(3):491-501, 1991 Jul.

2025-07-07 10:00:00